Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
67 Results for "
NFATc
" in MedChemExpress (MCE) Product Catalog:
Products (67)
67 Results for "NFATc" in MCE Product Catalog:
Cat. No.: HY-N5048
CAS No.: 122965-41-7
Synonyms: 6'-O-Galloyl paeoniflorin
Cat. No.: HY-175232
CAS No.: 488801-10-1
Research Areas:
GL64 is a selective agonist of ADGRD1 (EC50 = 3.98 μM). GL64 has low selectivity for ADGRD2, ADGRG5, ADGRG6, CELSR1, CELSR2, CELSR3, and ADGRG4 isoforms. GL64 activates ADGRD1 by mimicking the satchel sequence. GL64 regulates osteoclast maturation through the cAMP-PKA-NFATC1 pathway. GL64 effectively inhibits osteoclastogenesis and prevents bone loss both in vitro and in vivo. GL64 is useful in the study of osteoclast-related diseases .
Cat. No.: HY-W641445
CAS No.: 15533-81-0
Target:
Research Areas:
ELP-004 is a TRPC channel inhibitor and inhibtis TRPC channel-mediated Ca 2+ entry. ELP-004 is an osteoclast inhibitor and inhibits osteoclast differentiation. ELP-004 inhibits basal Ca 2+ and related NFATc1 translocation in inflammatory osteoclastogenesis. ELP-004 reduces bone erosion in a mouse model of rheumatoid arthritis .
Cat. No.: HY-W423191
CAS No.: 534-42-9
Synonyms: 4-O-α-D-Glucopyranosyl-D-gluconic acid
Synonyms: Nec-7
Target:
Research Areas:
Necrostatin-7 (Nec-7) is a Necroptosis inhibitor with an EC50 of 10.6 μM. Necrostatin-7 inhibits signal transduction from RANK to NFATc1 without affecting the activation of MAPK or NF-κB. Necrostatin-7 suppresses the expression levels of Acp5, Atp6v0d2, Ctsk and Dcstamp. Necrostatin-7 reduces myocardial infarction size, ameliorates adverse left ventricular remodeling, decreases myocardial wall stress, reduces the amount and length of scar tissue, and improves left ventricular function. Necrostatin-7 exerts cardioprotective effects in a rat model of permanent coronary artery occlusion. Necrostatin-7 can be used in research related to osteolytic bone diseases and myocardial infarction .
Target:
Research Areas:
NDMC101 is a potent osteoclastogenesis inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via DPP4 inhibition. NDMC101can be used for study of bone disorders, such as rheumatoid arthritis, and synovial inflammation et al .
Cat. No.: HY-RS09239
Target:
Research Areas:
NFATC2 Human Pre-designed siRNA Set A contains three designed siRNAs for NFATC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-16275
CAS No.: 908253-63-4
Synonyms: GS 9450; LB-84451
Target:
Research Areas:
Nivocasan (GS 9450; LB-84451) is a pan-caspase inhibitor that irreversibly arrests caspase-1 activity and inhibits that of caspase-8. Nivocasan inhibits IL-1β cleavage and blocks osteoclast differentiation. Nivocasan inhibits the protein expression of NFATc1 and CSTK .
Cat. No.: HY-N3071
CAS No.: 100234-59-1
Category:
Cat. No.: HY-107614G
CAS No.: 325465-93-8
Synonyms: 1-Oleoyl-sn-glycero-3-phosphate sodium (GMP); 1-Oleoyl-LPA sodium (GMP)
Cat. No.: HY-RS09238
Target:
Research Areas:
NFATC1 Human Pre-designed siRNA Set A contains three designed siRNAs for NFATC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS18427
Target:
Research Areas:
Nfatc1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nfatc1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P10889
CAS No.: 2366279-86-7
Target:
Research Areas:
Cat. No.: HY-162280
CAS No.: 3034024-77-3
Research Areas:
PROTAC BTK Degrader-9 is a potent BTK PROTAC degrader with a DC50 of 1.29 nM (in Mino cells at 4 h). PROTAC BTK Degrader-9 induces the formation of a stable ternary complex with BTK and the CRBN E3 ubiquitin ligase, thereby mediating proteasomal degradation of BTK in a CRBN-dependent manner. PROTAC BTK Degrader-9 downregulates the RANKL-activated BTK-PLCγ2-Ca 2+-NFATc1 signaling pathway. PROTAC BTK Degrader-9 alleviates alveolar bone resorption in periodontitis models of Mus musculus (house mouse). PROTAC BTK Degrader-9 can be used in research related to periodontitis .
Cat. No.: HY-N10076
CAS No.: 1191255-15-8
Category:
Cat. No.: HY-RS09241
Target:
Research Areas:
NFATC3 Human Pre-designed siRNA Set A contains three designed siRNAs for NFATC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
